Tri-Heal Blend (TB-500 + BPC-157 + KPV)
Tri-Heal is a three-peptide recovery blend combining TB-500 (thymosin ÎČ4 â systemic actin regulation and cell migration), BPC-157 (cytoprotection, angiogenesis, gut/tendon repair), and KPV (α-MSH C-terminal â anti-inflammatory, NF-ÎșB inhibition). Addresses tissue repair from three complementary angles in a single vial.
⥠Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard 8-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose | U-100 Units (mL) |
|---|---|---|
| Weeks 1â2 | 500 mcg (0.5 mg) | 3.3 units (0.033 mL)* |
| Weeks 3â4 | 1000 mcg (1.0 mg) | 6.7 units (0.067 mL)* |
| Weeks 5â6 | 1500 mcg (1.5 mg) | 10 units (0.10 mL) |
| Weeks 7â8 | 2000 mcg (2.0 mg) | 13.3 units (0.133 mL) |
*Precision Note: For doses â€10 units (â€0.10 mL), consider using 30-unit or 50-unit insulin syringes for improved readability and accuracy.
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to optimize syringe accuracy across all dose levels.
Extended 12-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose | U-100 Units (mL) |
|---|---|---|
| Weeks 1â2 | 500 mcg (0.5 mg) | 3.3 units (0.033 mL)* |
| Weeks 3â4 | 1000 mcg (1.0 mg) | 6.7 units (0.067 mL)* |
| Weeks 5â6 | 1500 mcg (1.5 mg) | 10 units (0.10 mL) |
| Weeks 7â8 | 2000 mcg (2.0 mg) | 13.3 units (0.133 mL) |
| Weeks 9â10 | 2500 mcg (2.5 mg) | 16.7 units (0.167 mL) |
| Weeks 11â12 | 3000 mcg (3.0 mg) | 20 units (0.20 mL) |
Extended 16-Week Protocol (3 mL = 15 mg/mL)
| Week | Daily Dose | U-100 Units (mL) |
|---|---|---|
| Weeks 1â2 | 500 mcg (0.5 mg) | 3.3 units (0.033 mL)* |
| Weeks 3â4 | 1000 mcg (1.0 mg) | 6.7 units (0.067 mL)* |
| Weeks 5â6 | 1500 mcg (1.5 mg) | 10 units (0.10 mL) |
| Weeks 7â8 | 2000 mcg (2.0 mg) | 13.3 units (0.133 mL) |
| Weeks 9â10 | 2500 mcg (2.5 mg) | 16.7 units (0.167 mL) |
| Weeks 11â12 | 3000 mcg (3.0 mg) | 20 units (0.20 mL) |
| Weeks 13â14 | 3500 mcg (3.5 mg) | 23.3 units (0.233 mL) |
| Weeks 15â16 | 4000 mcg (4.0 mg) | 26.7 units (0.267 mL) |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or direct stream onto the lyophilized cake.
- Gently swirl or roll until fully dissolved (do not shake vigorously).
- Label with date and concentration (15 mg/mL); refrigerate at 2â8 °C (35.6â46.4 °F), protected from light.
Supplies Needed
Plan based on an 8â16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Tri-Heal, 45 mg each) | 8 weeks (56 doses, ~70 mg total): 2 vials 12 weeks (84 doses, ~147 mg total): 4 vials 16 weeks (112 doses, ~252 mg total): 6 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (2 vials): 6 mL â 1 Ă 10 mL bottle 12 weeks (4 vials): 12 mL â 2 Ă 10 mL bottles 16 weeks (6 vials): 18 mL â 2 Ă 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs â recommend 2 Ă 100-count boxes 12 weeks: 168 swabs â recommend 2 Ă 100-count boxes 16 weeks: 224 swabs â recommend 3 Ă 100-count boxes |
For the early low-dose phases, a 30-unit or 50-unit syringe can make small-volume markings easier to distinguish.
How This Works
Tri-Heal stacks three complementary tissue repair mechanisms. TB-500 (Thymosin ÎČ4 peptide) â synthetic fragment of the 43-amino acid thymosin ÎČ4 â promotes actin polymerization and cell migration to wound sites, reducing inflammation via NF-ÎșB downregulation and stimulating angiogenesis and re-epithelialization. Its systemic distribution makes it effective for body-wide healing contexts.
BPC-157 (Body Protection Compound 157) acts cytoprotectively: it upregulates VEGFR2 (angiogenesis at injury), promotes fibroblast and tendon-cell outgrowth, stabilizes the nitric-oxide system, and provides gut mucosal protection. BPC-157 and TB-500 have complementary cellular targets â together they cover broader aspects of the repair cascade than either alone.
KPV (Lys-Pro-Val â the C-terminal tripeptide of α-MSH) blocks NF-ÎșB nuclear translocation, reducing TNF-α, IL-6, and IL-1ÎČ. Its direct anti-inflammatory contribution reduces the inflammatory microenvironment that delays healing, making the combined formulation particularly useful for chronic inflammatory conditions alongside acute repair.
Potential Benefits & Side Effects
Potential Benefits
- Triple mechanism: cell migration (TB-500) + angiogenesis/cytoprotection (BPC-157) + NF-ÎșB inhibition (KPV).
- Broader repair coverage than Wolverine (BPC+TB-500) due to KPV anti-inflammatory addition.
- KPV particularly useful for gut inflammation, IBD, and systemic inflammatory conditions.
- Convenient single vial vs three separate injections.
- TB-500's systemic distribution ensures body-wide healing support.
- BPC-157 covers gut, tendon, ligament, neural, and vascular repair models.
Side Effect Profile
- Generally well-tolerated â all three components have favorable safety profiles.
- Injection-site reactions.
- WADA prohibited (BPC-157 and TB-500 components).
- No established long-term safety data for the combination.
- Theoretical concern: sustained angiogenesis with occult malignancy.
- KPV component: excellent safety â naturally occurring α-MSH fragment.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | â20°C (â4°F) | â20°C, up to 24 months |
| Reconstituted | 2â8°C | Up to 14 days |